Cargando…
Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial
Altered martial indices before orthopedic surgery are associated with higher rates of complications and greatly affect the patient’s functional ability. Oral supplements can optimize the preoperative martial status, with clinical efficacy and the patient’s tolerability being highly dependent on the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071340/ https://www.ncbi.nlm.nih.gov/pubmed/32024027 http://dx.doi.org/10.3390/nu12020386 |
_version_ | 1783506179495821312 |
---|---|
author | Briguglio, Matteo Hrelia, Silvana Malaguti, Marco De Vecchi, Elena Lombardi, Giovanni Banfi, Giuseppe Riso, Patrizia Porrini, Marisa Romagnoli, Sergio Pino, Fabio Crespi, Tiziano Perazzo, Paolo |
author_facet | Briguglio, Matteo Hrelia, Silvana Malaguti, Marco De Vecchi, Elena Lombardi, Giovanni Banfi, Giuseppe Riso, Patrizia Porrini, Marisa Romagnoli, Sergio Pino, Fabio Crespi, Tiziano Perazzo, Paolo |
author_sort | Briguglio, Matteo |
collection | PubMed |
description | Altered martial indices before orthopedic surgery are associated with higher rates of complications and greatly affect the patient’s functional ability. Oral supplements can optimize the preoperative martial status, with clinical efficacy and the patient’s tolerability being highly dependent on the pharmaceutical formula. Patients undergoing elective hip/knee arthroplasty were randomized to be supplemented with a 30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic acid. The tolerability was 2.7% among treated patients. Adjustments for confounding factors, such as iron absorption influencers, showed a relevant response limited to older patients (≥ 65 years old), whose uncharacterized Hb loss was averted upon treatment with iron formula. Older patients with no support lost −2.8 ± 5.1%, while the intervention group gained +0.7 ± 4.6% of circulating hemoglobin from baseline (p = 0.019). Gastrointestinal diseases, medications, and possible dietary factors could affect the efficacy of iron supplements. Future opportunities may consider to couple ferric pyrophosphate with other nutrients, to pay attention in avoiding absorption disruptors, or to implement interventions to obtain an earlier martial status optimization at the population level. |
format | Online Article Text |
id | pubmed-7071340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70713402020-03-19 Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial Briguglio, Matteo Hrelia, Silvana Malaguti, Marco De Vecchi, Elena Lombardi, Giovanni Banfi, Giuseppe Riso, Patrizia Porrini, Marisa Romagnoli, Sergio Pino, Fabio Crespi, Tiziano Perazzo, Paolo Nutrients Article Altered martial indices before orthopedic surgery are associated with higher rates of complications and greatly affect the patient’s functional ability. Oral supplements can optimize the preoperative martial status, with clinical efficacy and the patient’s tolerability being highly dependent on the pharmaceutical formula. Patients undergoing elective hip/knee arthroplasty were randomized to be supplemented with a 30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic acid. The tolerability was 2.7% among treated patients. Adjustments for confounding factors, such as iron absorption influencers, showed a relevant response limited to older patients (≥ 65 years old), whose uncharacterized Hb loss was averted upon treatment with iron formula. Older patients with no support lost −2.8 ± 5.1%, while the intervention group gained +0.7 ± 4.6% of circulating hemoglobin from baseline (p = 0.019). Gastrointestinal diseases, medications, and possible dietary factors could affect the efficacy of iron supplements. Future opportunities may consider to couple ferric pyrophosphate with other nutrients, to pay attention in avoiding absorption disruptors, or to implement interventions to obtain an earlier martial status optimization at the population level. MDPI 2020-01-31 /pmc/articles/PMC7071340/ /pubmed/32024027 http://dx.doi.org/10.3390/nu12020386 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Briguglio, Matteo Hrelia, Silvana Malaguti, Marco De Vecchi, Elena Lombardi, Giovanni Banfi, Giuseppe Riso, Patrizia Porrini, Marisa Romagnoli, Sergio Pino, Fabio Crespi, Tiziano Perazzo, Paolo Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial |
title | Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial |
title_full | Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial |
title_fullStr | Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial |
title_full_unstemmed | Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial |
title_short | Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial |
title_sort | oral supplementation with sucrosomial ferric pyrophosphate plus l-ascorbic acid to ameliorate the martial status: a randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071340/ https://www.ncbi.nlm.nih.gov/pubmed/32024027 http://dx.doi.org/10.3390/nu12020386 |
work_keys_str_mv | AT brigugliomatteo oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT hreliasilvana oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT malagutimarco oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT devecchielena oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT lombardigiovanni oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT banfigiuseppe oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT risopatrizia oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT porrinimarisa oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT romagnolisergio oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT pinofabio oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT crespitiziano oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial AT perazzopaolo oralsupplementationwithsucrosomialferricpyrophosphatepluslascorbicacidtoamelioratethemartialstatusarandomizedcontrolledtrial |